Ninety One UK Ltd Has $24.11 Million Stake in Stryker Corporation $SYK

Key Points

• Ninety One UK Ltd reduced its stake in Stryker Corporation by 10.3%, holding 60,948 shares valued at approximately $24.11 million as of its latest SEC filing.
• Insider trading reports revealed significant share sales, with Director Ronda E. Stryker selling 200,000 shares for about $75.29 million, representing a 5.84% decrease in ownership.
• Stryker has set its FY 2025 earnings guidance between $13.400 and $13.600 EPS, with analysts predicting an EPS of $13.47 for the current fiscal year.

Ninety One UK Ltd trimmed its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 10.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,948 shares of the medical technology company's stock after selling 7,035 shares during the period. Ninety One UK Ltd's holdings in Stryker were worth $24,113,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Goodman Advisory Group LLC acquired a new stake in shares of Stryker in the first quarter worth $32,000. City Holding Co. boosted its holdings in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after purchasing an additional 74 shares during the period. Ridgewood Investments LLC grew its position in Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company's stock worth $36,000 after purchasing an additional 30 shares during the last quarter. Ransom Advisory Ltd bought a new position in shares of Stryker during the 1st quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Stryker during the first quarter valued at about $40,000. 77.09% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Trading Down 1.5%

Shares of SYK stock opened at $364.07 on Thursday. The company has a market capitalization of $139.19 billion, a P/E ratio of 48.22, a P/E/G ratio of 2.66 and a beta of 0.95. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average price of $384.08 and a 200 day moving average price of $379.01.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $5.92 billion. During the same period in the prior year, the firm earned $2.81 earnings per share. The company's quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker's payout ratio is currently 44.50%.

Analyst Ratings Changes

SYK has been the topic of a number of recent research reports. Rothschild Redb raised Stryker to a "hold" rating in a research report on Thursday, September 18th. BTIG Research reissued a "buy" rating on shares of Stryker in a report on Monday, July 14th. Evercore ISI upped their target price on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Wells Fargo & Company lifted their price target on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Finally, Truist Financial set a $415.00 price target on shares of Stryker and gave the company a "hold" rating in a report on Monday, August 4th. Fourteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $430.33.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.